Isoniazid for latent tuberculosis infection: Approaching 40 and reaching its prime

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 4, 2003, Pages 412-413

  Nolan, Charles M ^a  

^a Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HIGH RISK POPULATION; HUMAN; LIVER TOXICITY; MYCOBACTERIUM TUBERCULOSIS; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG MONITORING; HUMANS; ISONIAZID; SAFETY; TUBERCULOSIS, PULMONARY;

EID: 0042328180     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2306004     Document Type: Editorial

References (16)

1. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970;26:28-106.
2. Garabaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972;106:357-364.
3. Taylor WC, Aronson MD, Delbanco TL. Should young adults with a positive tuberculin test take isoniazid? Ann Intern Med 1981;94:808.
4. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis 1988;137:215-220.
5. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992;145:494-497.
6. American Thoracic Society/Centers for Disease Control and Prevention. Targeted testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-S247.
7. American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis 1983;127:790-796.
8. Leff DR, Leff AR. Tuberculosis control policies in major metropolitan health departments in the United States. Am J Respir Crit Care Med 1997;156:1487-1494.
9. Salpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med 1993;159:560-564.
10. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:10145-10148.
11. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003;168:443-447.
12. Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
13. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu LP, Loddenkemper R, Ravigloione MC. European framework for tuberculosis control and elimination in countries with a low incidence: recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002;19:765-775.
14. Nolan CM. Community-wide implementation of targeted testing and treatment of latent tuberculosis infection. Clin Infect Dis 1999;29:880-887.
15. CDC. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations: United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50:733-735.
16. Manabe YC, Bishai WR. Latent Mycobacterium tuberculosis: persistence, patience, and winning by waiting. Nat Med 2000;6:1327-9.